Literature DB >> 25252041

Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry.

Ovidiu Chioncel1, Andrew P Ambrosy, Serban Bubenek, Daniela Filipescu, Dragos Vinereanu, Antoniu Petris, Ruxandra Christodorescu, Cezar Macarie, Mihai Gheorghiade, Sean P Collins.   

Abstract

AIM: The objective of this study was to evaluate the clinical presentation, inpatient management, and in-hospital outcome of patients hospitalized for acute heart failure syndromes (AHFS) and classified as pulmonary edema (PE).
METHODS: The Romanian Acute Heart Failure Syndromes (RO-AHFS) study was a prospective, national, multicenter registry of all consecutive patients admitted with AHFS over a 12-month period. Patients were classified at initial presentation by clinician-investigators into the following clinical profiles: acute decompensated HF, cardiogenic shock, PE, right HF, or hypertensive HF.
RESULTS: RO-AHFS enrolled 3224 patients and 28.7% (n = 924) were classified as PE. PE patients were more likely to present with pulmonary congestion, tachypnea, tachycardia, and elevated systolic blood pressure and less likely to have peripheral congestion and body weight increases. Mechanical ventilation was required in 8.8% of PE patients. PE patients received higher doses (i.e. 101.4 ± 27.1 mg) of IV furosemide for a shorter duration (i.e. 69.3 ± 22.3 hours). Vasodilators were given to 73.6% of PE patients. In-hospital all-cause mortality (ACM) in PE patients was 7.4%, and 57% of deaths occurred on day one. Increasing age, concurrent acute coronary syndromes, life-threatening ventricular arrhythmias, elevated BUN, left bundle branch block, inotrope therapy, and requirement for invasive mechanical ventilation were independent risk factors for ACM.
CONCLUSIONS: In this national registry, the PE profile was found to be a high-acuity clinical presentation with distinctive treatment patterns and a poor short-term prognosis. Advances in the management of PE may necessitate both the development of novel targeted therapies as well as systems-based strategies to identify high-risk patients early in their course.

Entities:  

Mesh:

Year:  2016        PMID: 25252041     DOI: 10.2459/JCM.0000000000000192

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  4 in total

1.  Conservative fluid management prevents age-associated ventilator induced mortality.

Authors:  Joseph A Herbert; Michael S Valentine; Nivi Saravanan; Matthew B Schneck; Ramana Pidaparti; Alpha A Fowler; Angela M Reynolds; Rebecca L Heise
Journal:  Exp Gerontol       Date:  2016-05-14       Impact factor: 4.032

2.  Pulmonary Oedema-Therapeutic Targets.

Authors:  Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Mihai Gheorghiade; Gerasimos Filippatos
Journal:  Card Fail Rev       Date:  2015-04

Review 3.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

4.  Intravenous furosemide vs nebulized furosemide in patients with pulmonary edema: A randomized controlled trial.

Authors:  Hasan Barzegari; Ali Khavanin; Ali Delirrooyfard; Somayeh Shaabani
Journal:  Health Sci Rep       Date:  2021-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.